Literature DB >> 19625153

Simultaneous analysis of liposomal doxorubicin and doxorubicin using capillary electrophoresis and laser induced fluorescence.

Hee Seung Kim1, Irving W Wainer.   

Abstract

A method based on a capillary electrophoresis with laser induced fluorescence detection was developed and validated for simultaneous separation of doxorubicin (DOX) and liposomal encapsulated DOX. The separation was accomplished using a fused silica capillary (60cm in total length, 75microm I.D.) and potassium phosphate buffer [12.5mM, pH 7.4] as the running buffer. The effect of sample preparation conditions on maintaining liposomal integrity was also investigated. The limit of detection for DOX was 0.1microg/ml and the precision and accuracy of CE/LIF method was within the ranges of FDA guidelines. The validated method was successfully used to quantify DOX in human plasma using a direct injection of a 4-fold dilution of spiked liposomal DOX in human plasma. Copyright 2009. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19625153      PMCID: PMC2962568          DOI: 10.1016/j.jpba.2009.06.028

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  7 in total

1.  The liposomal formulation of doxorubicin.

Authors:  Sheela A Abraham; Dawn N Waterhouse; Lawrence D Mayer; Pieter R Cullis; Thomas D Madden; Marcel B Bally
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

2.  Selective determination of the doxorubicin content of individual acidic organelles in impure subcellular fractions.

Authors:  Yun Chen; Richard J Walsh; Edgar A Arriaga
Journal:  Anal Chem       Date:  2005-04-15       Impact factor: 6.986

Review 3.  Liposomal doxorubicin.

Authors:  P G Tardi; N L Boman; P R Cullis
Journal:  J Drug Target       Date:  1996       Impact factor: 5.121

4.  Distribution of zeptomole-abundant doxorubicin metabolites in subcellular fractions by capillary electrophoresis with laser-induced fluorescence detection.

Authors:  Adrian B Anderson; Chanda M Ciriacks; Kathryn M Fuller; Edgar A Arriaga
Journal:  Anal Chem       Date:  2003-01-01       Impact factor: 6.986

5.  Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study.

Authors:  Klaus Mross; Bernward Niemann; Ulrich Massing; Joachim Drevs; Clemens Unger; Rupinder Bhamra; Christine E Swenson
Journal:  Cancer Chemother Pharmacol       Date:  2004-08-21       Impact factor: 3.333

Review 6.  Cardiac safety of liposomal anthracyclines.

Authors:  Gerald Batist
Journal:  Cardiovasc Toxicol       Date:  2007       Impact factor: 3.231

7.  Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer.

Authors:  Christine E Swenson; Lois E Bolcsak; Gerald Batist; Troy H Guthrie; Katherine H Tkaczuk; Harold Boxenbaum; Lauri Welles; Shein-Chung Chow; Rupinder Bhamra; Philip Chaikin
Journal:  Anticancer Drugs       Date:  2003-03       Impact factor: 2.248

  7 in total
  3 in total

1.  Sensitive analysis of doxorubicin and curcumin by micellar electromagnetic chromatography with a double wavelength excitation source.

Authors:  Xiao Yu; Wanxiang Yu; Xiufen Han; Zuanguang Chen; Shumei Wang; Haiyun Zhai
Journal:  Anal Bioanal Chem       Date:  2020-10-28       Impact factor: 4.142

2.  Apoferritin as an ubiquitous nanocarrier with excellent shelf life.

Authors:  Simona Dostalova; Katerina Vasickova; David Hynek; Sona Krizkova; Lukas Richtera; Marketa Vaculovicova; Tomas Eckschlager; Marie Stiborova; Zbynek Heger; Vojtech Adam
Journal:  Int J Nanomedicine       Date:  2017-03-24

3.  Development of a method to quantify total and free irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) for pharmacokinetic and bio-distribution studies after administration of irinotecan liposomal formulation.

Authors:  Wenqian Yang; Zimeng Yang; Jieru Liu; Dan Liu; Yongjun Wang
Journal:  Asian J Pharm Sci       Date:  2018-09-11       Impact factor: 6.598

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.